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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of can-
cer mortality worldwide, with approximately 700,000 new cases 
diagnosed every year (1, 2). HCC typically develops in patients with 
chronic liver disease. Among these, viral hepatitis, nonalcoholic 
fatty liver disease, and alcoholic liver disease are the leading causes 
of HCC (2). Chronic liver injury, triggering permanent hepatocellu-
lar damage, hepatocyte regeneration, and inflammation, is thought 
to be the unifying principle that promotes carcinogenesis in these 
pathophysiologically distinct diseases. In the developing liver, bipo-
tent hepatoblasts differentiate into hepatocytes and cholangiocytes 
and function as a main cellular source for both lineages (3). However, 
in the adult liver, cell turnover is minimal, and bipotent progenitors 
are typically absent (3). In contrast to many organs that have a hierar-
chical organization depending on well- defined stem cell populations, 
such as intestine and skin (4–6), the fully differentiated hepatocyte is 
endowed with an almost infinite capacity to regenerate (7). Accord-
ingly, regeneration following most types of injury or after partial 
hepatectomy is achieved from the hepatocyte pool without major 
contribution of progenitor cells (3, 8). However, when liver injury is 
chronic and when the ability of mature hepatocytes to proliferate is 
blocked, a reserve cell compartment located within the biliary com-
partment — often termed oval cells or liver progenitor cells (LPCs) — 
expands in patients and in experimental injury models and may con-
tribute to the formation of hepatocytes (3, 7, 9–13). However, several 
recent fate-tracing studies have challenged a major role for the LPC/
biliary compartment in the formation of hepatocytes, showing either 
no or only very little contribution to the hepatocyte pool (8, 14–18). On 
the other hand, the LPC/biliary compartment is capable of generat-
ing functional hepatocytes in zebrafish (19), indicating that its contri-
bution may be model-, disease-, or species-specific. Moreover, recent 
studies have suggested that hepatic stellate cells (HSCs) may function 
as multipotent progenitor cells that generate functional hepatocytes 
and cholangiocytes (20). Thus, 3 potential cellular sources — hepa-
tocytes, the LPC/biliary compartment and HSCs — may, in theory, 
function as progenitor cells and the cellular source for newly gener-
ated hepatocytes.
In view of the key roles of stem and progenitor cells in the 
maintenance of many tissues, it is not surprising that these are 
also the cells of origin in cancer of the intestine (21, 22), skin (23, 
24), and hematopoietic system (25). In contrast, the cellular origin 
of HCC remains elusive, with the above-discussed contributors 
to homeostasis and regeneration of the adult liver, namely hepa-
tocytes, the LPC/biliary compartment, and HSCs, representing 
potential sources. Of note, the expansion of LPCs has consistently 
been noted after treatment with hepatic carcinogens (26, 27), 
which has led to the suggestion that HCC may be derived from the 
LPC/biliary compartment (26, 28, 29). Moreover, the expression 
of progenitor markers and accumulation of LPCs are commonly 
observed in rodent models as well as in human HCC (30, 31). 
Therefore, the reemergence of LPCs in the chronically injured 
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Rosa26RYFP locus and to permanent expression of yellow flu-
orescent protein (YFP) in OPN-expressing cells. As reported 
elsewhere (15), upon tamoxifen injection, YFP expression is 
restricted to the LPC/biliary compartment and does not occur 
in hepatocytes, stellate cells, or Kupffer cells (Supplemental Fig-
ure 1; supplemental material available online with this article; 
doi:10.1172/JCI77995DS1). Using this system, between 69% and 
84% of the LPC/biliary compartment and its progeny were per-
manently tagged with YFP in this study (Figure 1C, Figure 2D, 
and Supplemental Figure 1A), and thus, development of YFP+ 
HCC would indicate a progenitor/biliary origin.
First, HCCs were induced by chronic administration of dieth-
ylnitrosamine (DEN), resulting in HCC development in the setting 
of chronic injury, inflammation, and fibrosis (36). Tamoxifen was 
injected on postpartum (pp) day 21 (n = 44), followed after a 4-week 
washout period by repeated administration of DEN. At the time of 
sacrifice, macroscopic tumors were observed in all livers (Figure 
1A and Table 1). These tumors were well delineated and exhib-
ited enlargement of hepatocytic plates, a high proliferative index, 
disruption of the reticulin network, absence of portal tracts, and 
focal expression of α-fetoprotein (AFP) and OPN (Figure 1, B–D). 
Altogether, 250 tumors were histologically evaluated by an exper-
imental pathologist (C. Sempoux) and diagnosed as HCC. YFP 
immunostaining was performed to determine the cellular source 
of HCC. In all 250 tumors, YFP expression was missing (Table 1) 
and only seen in CK-19–positive and OPN-positive bile duct cells 
and in the ductular reaction (DR) that surrounds the tumors (Fig-
liver may link regeneration to hepatocarcinogenesis. As HCC with 
a progenitor signature is clinically more aggressive, it has been 
suggested that the progenitor origin of HCC determines tumor 
biology and negatively affects outcome (31). Importantly, both 
LPCs and hepatocytes have the capacity to generate tumors in vivo 
when transduced with H-RAS and SV40LT (32). However, the rel-
ative contribution of these 2 cell types to cancer formation in the 
context of chronic hepatocellular injury in vivo remains unknown. 
The high degree of plasticity in the liver is further highlighted by 
recent studies showing that cholangiocarcinoma can be derived 
not only from cholangiocytes (33) but also from hepatocytes (34, 
35). Given these findings in cholangiocarcinoma, it is conceiv-
able that there are also multiple cellular sources for HCC. Using 
complementary strategies to label the LPC/biliary compartment, 
hepatocytes, and HSCs, we demonstrate that hepatocytes, but nei-
ther the LPC/biliary compartment nor HSCs, function as a cellu-
lar source for HCC. Moreover, LPCs found in HCC were derived 
from hepatocytes, suggesting that hepatocyte-derived HCC may 
dedifferentiate into an LPC-like immature phenotype.
Results
HCC does not originate from the LPC/biliary compartment. To test 
the hypothesis that HCC is derived from the LPC/biliary com-
partment, we used tamoxifen-inducible osteopontin-iCreERT2 
(Opn-iCreERT2) Rosa26RYFP mice (referred to herein as Opn-
CreERT2 mice) to label progenitor and biliary cells. Tamoxifen 
injection in the postnatal period leads to recombination of the 
Figure 1. HCC does not derive from the LPC/biliary compartment. Tamoxifen-treated Opn-CreERT2 mice expressing the YFP Cre reporter were subjected 
to 25 injections of DEN (n = 33). (A and B) Mice developed macroscopically (A) and microscopically (B) visible HCCs. Tam, tamoxifen. (C and D) While the 
K19-positive biliary/LPC compartment was tagged efficiently by YFP, no HCCs were YFP positive. HCCs were delineated by an α-SMA–positive border and 
infiltrated by myofibroblasts; HCCs displayed a disrupted reticulin meshwork, high Ki67 expression levels, focally expressed OPN and AFP, and were sur-
rounded by a patchy K19-positive and YFP-positive DR. Scale bars: 1 cm (A and B); 100 μm (D). Chol, cholangiocyte; NT, nontumor; T, tumor.
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combination with Rosa26loxP-mTom-stop-loxP–mGFP (mTom-mGFP) or 
Rosa26loxP-stop-loxP–ZsGreen1 (ZsGreen) Cre reporter mice. In ZsGreen Cre 
reporter mice, this approach labeled more than 96% of hepato-
cytes, without labeling any other hepatic compartment including 
F4/80-positive Kupffer cells, the cytokeratin-positive biliary and 
LPC compartments, desmin-positive HSCs, or endomucin-pos-
itive endothelial cells, as determined by IHC and confocal imag-
ing (Supplemental Figure 4, A and C–G). This analysis was fur-
ther confirmed by quantitative PCR (qPCR) of FACS-sorted cells 
that expressed the green fluorescent Cre reporter ZsGreen and 
showed at least the same level of Alb and Ttr expression as did 
primary hepatocytes, but virtually no expression of cholangiocyte 
markers Krt7 and Krt19, HSC markers Des and Lrat, endothelial 
cell markers Pecam (CD31) and Vwf, or macrophage markers Emr1 
(F4/80) and Cd68 (Supplemental Figure 4B). Together, these data 
confirm an efficient and highly specific labeling of hepatocytes by 
AAV8-Tbg-Cre, similar to what was observed in previous studies 
(40, 41). Following AAV8-Tbg-Cre infection on pp day 12, we used 
either the single agent DEN (data not shown) or the combination 
of DEN+CCl4 to trigger hepatocarcinogenesis. These well-estab-
lished protocols resulted in the development of well-delineated 
tumors in 100% of mice (Figure 3A). Although the average hepa-
tocyte-labeling rate in the mTom-mGFP reporter mice was slightly 
below 96%, we observed, macroscopically and microscopically, 
an average rate of 99.7% of mGFP-positive tumors (average of 
n = 10 mice, 185 of 186 mGFP-positive tumors), i.e., hepatocyte- 
derived tumors, in DEN+CCl4-treated mice (Figure 3, A–D, and 
Table 2). Because hepatocyte labeling did not reach 100%, and 
because we never observed any tumor arising from the LPC/bil-
iary compartment by our complementary LPC/biliary compart-
ment–labeling approaches, we consider it most likely that the sin-
gle GFP-negative tumor arose from unlabeled hepatocytes rather 
than from the LPC/biliary compartment. Although tumors were 
macroscopically entirely green, microscopic analysis revealed the 
presence of unrecombined, nonhepatocyte-derived Tomato-posi-
tive cells. These tomato-positive cells consisted predominantly of 
CD31-positive endothelial cells and F4/80-positive macrophages 
(Supplemental Figure 5). Tumors were clearly defined as HCCs by 
pathological examination, which showed loss of the normal hepatic 
reticulin and collagen IV staining pattern, increased expression 
ure 1, C and D). In a second model, HCCs were induced by a sin-
gle DEN injection into 15-day-old (day 15) Opn-CreERT2 mice. 
Tamoxifen was injected before (pp days 9–10; n = 16) or after (pp 
days 21–22; n = 25) DEN administration. The efficiency and spec-
ificity of the lineage tracing was equivalent (≈70%) and indepen-
dent of the time of tamoxifen administration, and macroscopic 
tumors developed (Supplemental Figure 2, A and B) in 50% and 
70% of the mice within 18 and 9 months, respectively (Table 1), 
consistent with the notion that tamoxifen treatment, in particular 
when given immediately before tumor induction, delays or inhibits 
tumor development (37). Two-hundred forty tumors induced by 
this method were diagnosed as HCC. YFP expression was absent 
in all HCCs (Table 1), while bile ducts and the DR found surround-
ing the tumors were YFP positive (Supplemental Figure 2, C and 
D). These findings were further confirmed in Opn-CreERT2 mice 
treated with the combination of DEN and CCl4, which mimics 
hepatocarcinogenesis in the setting of liver fibrosis (38). In this 
model, HCCs also displayed characteristic features such as loss of 
collagen IV staining, high proliferation, and expression of the pro-
genitor/hepatoblast genes Afp, Prom1, and H19 (Figure 2, A, B, and 
E). Again, none of the tumors were labeled with YFP, whereas bile 
ducts in nontumor liver were YFP positive (Figure 2, C and D, and 
Table 1). In a second model of LPC/biliary compartment labeling, 
achieved by the combination of tamoxifen-inducible K19-CreERT 
(39) and the Cre reporter mTom-mGFP, none of the arising DEN 
plus CCl4–induced (DEN+CCl4-induced) HCCs (0 of 219 tumors) 
were mGFP positive, i.e., derived from the K19-CreERT–labeled 
LPC/biliary compartment (Figure 2, F–I, Supplemental Figure 3, 
A–C, and Table 1). In summary, the absence of LPC/biliary com-
partment–labeled tumors confirms that in multiple genotoxic 
DEN-induced hepatocarcinogenesis models and in different Cre-
Tg mice, HCCs do not arise from LPCs or biliary cells.
Genotoxic HCC originates from hepatocytes. As we found no 
evidence for the LPC/biliary compartment serving as the cellular 
source of HCC, we next investigated the alternative hypothesis 
that hepatocytes constitute the cellular source for HCC. To selec-
tively label and trace hepatocytes during hepatocarcinogenesis, 
we used an adeno-associated virus serotype 8 (AAV8) expressing 
Cre recombinase under the control of the hepatocyte- specific 
thyroxin-binding globulin (TBG) promoter (AAV8-Tbg-Cre) in 
Table 1. Tracing of the LPC/biliary compartment in HCC models
Mouse HCC  
induction
Liver  
analyzed  
(n)
Livers  
with HCCs  
(%)
No. of HCCs  
analyzed per  
liver (min–max)
Total no.  
of HCCs 
analyzed
% of HCCs  
traced as having  
LPC origin
% of K19+ HCCs  
(no. of pos. HCCs/ 
no. of analyzed tumors)
% of A6+ HCCs  
(no. of pos. HCCs/  
no. of analyzed tumors)
Opn-CreERT2 TAM d 21 / DEN 25× 33 100% 1 to >25 >250 0 2% (5/250 analyzed) 14.7% (17/115 analyzed)
Opn-CreERT2 DEN d 15/TAM d 21–22 25 68% 1–20 >150 0 0% (0/150 analyzed) Not det.
Opn-CreERT2 DEN d 15/TAM d 9–10 16 50% 420 >90 0 0% (0/90 analyzed) 26% (13/50 analyzed)
Opn-CreERT2 TAM d 9–10/DEN d 15/
CCl4 20×
6 100% 1–15 30 0 0% (0/30 analyzed) 66.6% (20/30 analyzed)
Opn-CreERT2 CDE diet >1 yr 9 30% 1–2 4 0 0 Not det.
K19-CreERT TAM d 10, DEN+CCl4 5 100% 25–69 219 0 11.5% (15/131 analyzed) 35.1% (46/131 analyzed)
Ptenfl/fl - K19-CreERT Pten deletions in LPCs 
(TAM d 21)
4 0% NA NA NA NA NA
20×, 20 injections; 25×, 25 injections; NA, not applicable; Not det., not determined; min, minimum; max, maximum; pos., positive.
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order of magnitude higher expression of the progenitor and hepa-
toblast markers Afp and H19, and almost all also contained much 
higher levels of Prom1 (Figure 3G). These data clearly exclude the 
possibility that hepatocyte origin in the DEN+CCl4 model is due 
to the lack of a progenitor signature in these tumors. To addition-
ally address the possibility that LPC origin may only be revealed 
in models in which HCC arises in the setting of higher progenitor 
cell presence and turnover, we used the combination of DEN with 
either a choline-deficient, 0.15% ethionine-supplemented (CDE) 
diet or a 0.1% 3,5-diethoxycarbonyl-1,4-dihydro-collidin–supple-
mented (DDC-supplemented) diet (14, 15). Although the labeling 
of hepatocytes was less efficient in these experiments than in the 
above DEN+CCl4 experiments, 98.3% of DEN+CDE diet–induced 
tumors and 95.6% of DEN+DDC diet–induced tumors were mac-
roscopically and microscopically GFP positive (Supplemental Fig-
ure 7, A–D). When only mice with at least 90% hepatocyte labeling 
were included in the analysis, 100% of tumors were GFP positive 
(data not shown), again suggesting that the few GFP-negative 
of the proliferation marker Ki67, an altered expression pattern of 
Gp73, loss of β-catenin, and upregulation of glutamine synthetase 
(Figure 3E). Histological analysis revealed a wide range of growth 
patterns including trabecular, steatotic, and solid and cytoplas-
matic inclusions (Supplemental Figure 6A). Accordingly, tumors 
were diverse when analyzed by array comparative genomic hybrid-
ization (aCGH), which demonstrated chromosomal aberrations in 
each investigated mouse, with a wide range of genomic alterations 
rather than a specific pattern (Supplemental Figure 6B). Of note, 
comparison of genomic alteration in DEN+CCl4- induced HCCs 
with a well-characterized set of human cryptogenic HCCs (42) 
revealed gains and losses of loci in various chromosomal regions 
congruent with genomic alterations in human HCC (Supplemen-
tal Figure 6C), further confirming the relevance of the model 
used here. Moreover, tumors expressed high mRNA levels of 
genes that are typically elevated in HCC, including Gpc3, Golm1, 
mKi67, Tff3, and Tspan8 mRNA (Figure 3F). Importantly, every 
single DEN+CCl4-induced tumor we examined showed at least 1 
Figure 2. HCC does not derive from the LPC/biliary compartment in the DEN+CCl4 model. Tamoxifen-treated Opn-CreERT2 mice were treated with DEN 
followed by 20 injections (20×) of CCl4 (n = 6). (A and B) Representative macroscopic (A) and histological images (B) showing typical HCC features such as 
high Ki67 expression levels and disruption of the collagen IV meshwork. Col IV, collagen IV. (C and D) The cholangiocyte/LPC compartment was YFP posi-
tive, but no HCCs were YFP positive (n = 6). (E) HCC and progenitor/hepatoblast markers determined by qPCR. (F–I) mTom-mGFP Cre reporter mice  
(n = 5) were treated with tamoxifen, followed by administration of DEN and 20 injections of CCl4 for HCC induction. Representative images and fluorescent 
images of livers (F) and H&E- and GFP-stained liver sections at low (G) and high (H) magnification, demonstrating mGFP-positive ducts in nontumor areas 
but not in tumor areas. Quantification of GFP-labeled K19-positive cholangiocytes and tumors (n = 5) (I). Sac, sacrifice. Scale bars: 1 cm (A and F); 100 μm 
(B and G); 50 μm (C and H). **P < 0.01, ***P < 0.001 by Mann-Whitney U test.
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positive cholangiocytes, or endomucin-positive endothelial cells 
(Supplemental Figure 8A). As this model not only lacks the con-
founding effects of hepatocellular DEN metabolism but also 
incorporates an abundance of progenitor/hepatoblast markers in 
the injured liver (Figure 4H), it provides an ideal setting for deter-
mining in an unbiased manner the cell population from which 
HCCs originate in the chronically injured, inflamed, and fibrotic 
liver. All HCCs from Mdr2KO mice (n = 9 mice, 25 of 25 tumors) 
arose from AAV8-Tbg-Cre–labeled hepatocytes with macroscopic 
and microscopic ZsGreen tumor fluorescence (Figure 4, A–D, and 
Table 2) and colocalization of ZsGreen with HNF4α within tumors 
(Figure 4E). Tumors from Mdr2KO mice were typical HCCs, with 
altered collagen IV expression, high expression of the prolifera-
tion marker Ki67, and upregulation of the tumor markers Golm1, 
Tff3, and Tspn8 mRNA (Figure 4, F–H), as determined by IHC 
and qPCR. The few ZsGreen-negative cells within tumors were 
endomucin-positive endothelial cells and F4/80-positive Kupffer 
tumors in DEN+CDE and DEN+DDC experiments were a result of 
incomplete hepato cyte labeling rather than being LPC/biliary com-
partment derived. Similar to the DEN+CCl4 model, DEN+CDE- 
and DEN+DDC- induced tumors showed high expression of HCC 
markers and progenitor and hepatoblast markers (Supplemental 
Figure 7, E and F, and Table 2).
HCC originates from hepatocytes in nongenotoxic HCC models. 
To exclude the possibility that our observations on hepatocyte 
origin were specific to the models used or caused by preferential 
metabolism of carcinogens in hepatocytes, we additionally tested 
the cellular origin in DEN-free HCC models. For this purpose, 
we first investigated Mdr2KO mice, which spontaneously develop 
inflammation, fibrosis, and HCC, thus reproducing the sequence 
of events that lead to the majority of human HCCs (43). In the 
Mdr2KO model, AAV8-Tbg-Cre–mediated hepatocyte labeling 
via the ZsGreen Cre reporter exceeded 95.7%, without labeling 
desmin-positive HSCs, F4/80-positive Kupffer cells, cytokeratin- 
Figure 3. Genotoxic HCC derives from hepatocytes. mTom-mGFP Cre reporter mice (n = 10) were infected with AAV8-Tbg-Cre to selectively label hepa-
tocytes, followed by treatment with DEN and 20 injections of CCl4 for HCC induction. (A–C) Representative images and fluorescent images of livers from 
DEN+CCl4-treated mice (A) and H&E- and GFP-stained liver sections at low (B) and high (C) magnification, including an mTom-mGFP negative control. 
(D) Quantification of GFP-labeled hepatocytes and tumors (average of all mice, n = 10). (E) Typical HCC features were confirmed by collagen IV staining, 
increased Ki67 and glutamine synthetase levels, and altered Gp73 and β-catenin (β-Cat) staining. (F and G) HCC markers (F) and progenitor markers (G) were 
determined by qPCR. Scale bars: 1 cm (A); 1 mm (B); 50 μm (C); 300 μm (E). *P < 0.05, **P < 0.01, ***P < 0.01 by Kruskal-Wallis and Dunn’s post-hoc test.
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cells (Supplemental Figure 8B). To further confirm these findings 
in another nongenotoxic model, we determined whether hepa-
tocyte-specific deletion of Pten triggers HCC. PTEN is a tumor-
suppressor gene that shows reduced expression in approximately 
50% of human HCC cases and an inverse correlation with survival 
(44) and whose deletion by albumin-Cre — which deletes PTEN in 
both the hepatocyte and LPC/biliary compartment (Supplemen-
tal Figure 9) — triggers HCC development in mice (45). To pro-
vide evidence for hepatocytes as the cellular source of HCC in a 
genetic model, we either deleted Pten specifically in hepatocytes 
via AAV8-Tbg-Cre or in the LPC/biliary compartment via tamox-
ifen-inducible K19-CreERT (39). AAV8-Tbg-Cre–induced hepatoc-
yte-specific deletion of Pten resulted in the development of tumors 
with HCC features including increased expression of glypican 3, 
Ki67, pancytokeratin, and phosphorylated-AKT (p-AKT) (Supple-
mental Figure 10CCl4, A and B, and Table 2), and tumors were 
derived from hepatocytes, as demonstrated by green fluorescence 
(Supplemental Figure 10, C and D). By contrast, K19-driven Pten 
deletion resulted in an expansion of the cytokeratin-positive bil-
iary compartment but never led to HCC development (Supple-
mental Figure 10, E and F). These data again demonstrate that 
the LPC/biliary compartment is not endowed with the capacity 
to form HCCs in mice. Finally, we also subjected Opn-Cre mice 
to chronic treatment with a CDE-deficient diet as a complemen-
tary LPC/biliary compartment–labeling approach. This model 
was accompanied by a florid DR. HCCs were less common than in 
other models but were YFP negative and hence not of LPC origin 
(Supplemental Figure 10, G and H, and Table 1). Together, these 
data provide multiple lines of evidence that hepatocytes, and not 
the LPC/biliary compartment, are the cellular source for HCC in 
nongenotoxic tumor models.
HSCs do not represent a cellular source for HCC. Recent studies 
have suggested HSCs as an alternative source of LPCs and hepa-
tocytes (20). However, this concept remains controversial and is 
not supported by fate tracing in mice (46). To determine whether 
HSC-derived LPCs or hepatocytes might be the source for HCC, 
HSCs were labeled by Lrat-Cre in combination with ZsGreen or 
TdTomato mice, a system that efficiently and selectively tags 
HSCs in the liver (46). In line with our previous studies in multiple 
injury models (46), we did not detect a significant number of HSC- 
derived hepatocytes in mice that underwent injury-driven hepato-
carcinogenesis induced by DEN+CCl4 (data not shown). Moreover, 
we did not find any tumors that were derived from Lrat-Cre–labeled 
cells (Figure 5, A–C), with all fluorescent cells within tumors being 
desmin positive (Figure 5D) and HNF4α and cytokeratin negative 
(Supplemental Figure 11A). Similar observations were made in the 
Mdr2KO model, in which no tumor cell was derived from Lrat-Cre–
labeled HSCs (Figure 5, E, F, H, and Supplemental Figure 11B). In 
both models, tumors revealed typical HCC characteristics such as 
altered collagen IV and Gp73 expression patterns and increased 
Ki67 staining (Figure 5, C and G). While most tumors contained 
moderate numbers of Lrat-Cre–labeled cells, some tumors in both 
the DEN+CCl4 and Mdr2KO models displayed stronger accumu-
lation of Lrat-Cre–labeled, desmin-positive HSCs (Supplemental 
Figure 11, C and D). However, even in the few tumors that showed 
strong Cre reporter fluorescence, fluorescent cells colocalized with 
desmin, without any overlap of the Lrat-Cre–induced Cre reporter 
TdTomato with either HNF4α or cytokeratin (Supplemental Fig-
ure 11, E and F). These findings are consistent with our data on 
the exclusive contribution of hepatocytes to HCC formation in the 
DEN+CCl4 and the Mdr2KO models and further exclude the possi-
bility that HCCs originate from HSC-derived hepatocytes.
Progenitor cells within HCCs originate from hepatocytes. Con-
sistent with our data showing high mRNA expression of the pro-
genitor/hepatoblast markers Afp, Prom1, and H19 in tumors (Fig-
ure 2E, Supplemental Figure 3C, and Supplemental Figure 7F), 
we observed abundant A6- and AFP-positive cells, and to a lesser 
extent cyto keratin 19–positive (K19-positive) cells, within HCC 
Table 2. Hepatocyte tracing in HCC models
Mouse HCC  
induction
Liver analyzed 
(n)
Livers with 
HCCs (%)
Number of HCCs 
analyzed per 
liver (min–max)
Total no. 
of HCCs 
analyzed
% of HCCs 
traced as having 
hepatocyte origin
% of K9+ HCCs  
(no. of pos. HCCs/  
no. of analyzed tumors)
% of A6+ HCCs  
(no. of pos. HCCs/  
no. of analyzed tumors)
lox-stop-lox mTom-mGFP 
Cre reporter mice plus 
AAV8-Opn-CreERT2
DEN+CCl4 10 100% 1–35 186 99.5%  
(185/186)
17.1%  
(19/111 analyzed)
36.9%  
(41/111 analyzed)
lox-stop-lox mTom-mGFP 
Cre reporter mice plus 
AAV8-Opn-CreERT2
DEN+CDE 4 100% 19–41 118 98.3%  
(116/118)
14.5%  
(12/83 analyzed)
56.6%  
(47/83 analyzed)
lox-stop-lox mTom-mGFP 
Cre reporter mice plus 
AAV8-Opn-CreERT2
DEN+DDC 3 100% 5–22 46 95.7%  
(44/46)
11.4%  
(4/35 analyzed)
40.0%  
(14/35 analyzed)
Mdr2KO - ZsGreen  
Cre reporter mice plus 
AAV8-Tbg-Cre
Mdr2KO 9 100% 1–6 25 100%  
(25/25)
38.9%  
(7/18 analyzed)
66.7%  
(12/18 analyzed)
Ptenfl/fl - mTom-mGFP  
Cre reporter mice
Pten deletion 
(AAV8-Tbg-Cre)
8 100% 2–4 12 100%  
(123/123)
Not det. Not det.
Ptenfl/fl - mTom-mGFP  
Cre reporter mice
Pten deletion 
(AAV8-Tbg-Cre)
4 100% 15–44 123 100%  
(123/123)
Not det. Not det.
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nodules in all DEN-based models (Figure 1D, Figure 6, A–C, E, 
F, Supplemental Figure 12, Supplemental Figure 13, A and B, and 
Supplemental Figure 14, A and B). Instead of interpreting these 
markers as a sign of LPC origin, we investigated the alternative 
hypothesis that AFP-, A6-, and K19-positive cells within HCCs 
may be hepatocyte- derived cells that underwent dedifferentiation. 
Confocal microscopy demonstrated that in AAV8-Tbg-Cre mice, 
virtually all A6-positive cells within DEN+CCl4-, DEN+DDC-, and 
DEN+CDE-induced tumors also coexpressed mGFP (Figure 6A, 
Supplemental Figure 12, Supplemental Figure 13B, and Supplemen-
tal Figure 14B), thus demonstrating their hepatocytic origin. These 
data were confirmed by AFP and K19 staining, which showed that 
AFP-positive cells (Figure 6C, Supplemental Figure 12, Supple-
mental Figure 13A, and Supplemental Figure 14A) and K19-positive 
cells (Figure 6B and Supplemental Figure 12) within tumors were 
mGFP positive and therefore hepatocyte derived. In contrast, there 
were almost no A6-positive cells that coexpressed mGFP outside 
of the tumors (Figure 6, A and D, Supplemental Figure 12, Supple-
mental Figure 13B, and Supplemental Figure 14B). Moreover, only 
a small amount of K19-positive cells outside the tumor areas were 
mGFP positive (Figure 6, B and D). Similar findings were made 
in the Mdr2KO model, in which most K19-positive and A6-positive 
cells within tumors, but not in the surrounding liver, were hepato-
cyte derived (Supplemental Figure 15, A and B). Consistent with 
these findings, we observed in Opn-CreERT2 mice that A6-positive 
cells within tumors were YFP negative, whereas the A6-positive 
DR surrounding the tumors was YFP positive (Figure 6, E and H). 
K19 staining confirmed that YFP-positive cells outside the tumors 
expressed K19, while K19-positive cells within the HCCs were YFP 
negative (Figure 6, F and H, and Supplemental Figure 2, C and D). 
AFP-positive cells were only found within the tumors and were YFP 
negative (Figure 6G). Together, these data suggest that A6-, K19-, 
and AFP-positive cells within tumors are hepatocyte derived, but 
that most A6- and K19-positive cells outside the tumors (AFP-pos-
itive cells were extremely rare outside the tumors; Figure 6D) were 
derived from the LPC/biliary compartment.
Figure 4. HCCs derive from hepatocytes in the Mdr2KO HCC model. Mdr2KO mice expressing the ZsGreen Cre reporter (n = 9) were infected with AAV8-Tbg-Cre 
to selectively label hepatocytes and sacrificed at 12 to 14 months of age. (A–C) Representative images and fluorescent images of whole livers from Mdr2KO 
mice (A) as well as H&E- and Hoechst-stained frozen liver sections at low (B) and high (C) power, including a ZsGreen negative control. (D) Quantification of 
GFP-labeled hepatocytes and tumors (average of all mice). (E) Costaining demonstrated that HNF4α-positive tumor cells were ZsGreen positive. (F) Typical 
HCC features were confirmed by increased Ki67 expression and altered collagen IV staining. (G and H) HCC markers (G) and progenitor markers (H) were deter-
mined by qPCR (n = 5 control livers and n = 14 tumors). Scale bars: 1 cm (A); 300 μm (B); 50 μm (C and E); 500 μm (F). **P < 0.01 by Mann-Whitney U test.
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support of this, both cell populations have been demonstrated to 
have the ability to induce HCC when transduced with a combi-
nation of H-RAS and SV40LT (32). Despite their known capacity 
to differentiate into HCCs after forced expression of oncogenes, 
the relative contribution of these cell types to HCC formation in 
endogenous HCC models, which occur in the setting of chronic 
injury and inflammation, remains unknown. Our fate-tracing 
data support the hypothesis that hepatocytes constitute the main 
cellular source of HCC in mice and that the LPC/biliary compart-
ment does not function as a source of HCC in mice. Our analysis 
not only includes several models in which HCCs expressed an 
Discussion
Despite its nomenclature, the cellular source of HCC remains 
elusive. Hepatocytes are not only the target of oncogenic hepa-
totrophic viruses and most hepatotoxins, but also have a stem 
cell–like capacity for nearly infinite regeneration (47), making 
them a primary candidate for the cellular source of HCC. How-
ever, the LPC/biliary compartment has the capacity to differen-
tiate into hepatocytes (10, 13, 19), and LPCs are commonly found 
in dysplastic lesions and HCCs (30, 31, 48), suggesting that the 
LPC/biliary compartment could be an alternative source for sub-
sets of HCCs, in particular those with a progenitor signature. In 
Figure 5. HCCs are not derived from HSCs. (A–D) Lrat-Cre Tg mice expressing the ZsGreen Cre reporter (n = 4) were treated with DEN and 20 injections 
of CCl4 for HCC induction. Representative images and fluorescent images of livers from DEN+CCl4-treated mice (A) as well as H&E- and Hoechst-stained 
frozen liver sections at low and high magnification show green fluorescent HSCs but no green fluorescent tumor cells derived from HSCs (B). Typical HCC 
features were confirmed by collagen IV staining and increased Ki67 expression (C). ZsGreen-positive cells colocalized with the HSC marker desmin (D). 
(E–H) Mdr2KO mice expressing Lrat-Cre and the ZsGreen Cre reporter (n = 8) were sacrificed at 12 months of age. Representative images and fluorescent 
images of whole livers (E) as well as H&E- and Hoechst-stained frozen liver sections at low and high magnification show green fluorescent HSCs but no 
green fluorescent tumor cells derived from HSCs (F). Typical HCC features were confirmed by increased Ki67 expression and altered collagen IV staining (G). 
ZsGreen-positive cells colocalized with the HSC marker desmin (H). Scale bars: 5 mm (A and E); 500 μm (B, left panel and F, left panel); 50 μm (B, right 
panel and F, right panel); 500 μm (C and G); 50 μm (D and H).
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theless observed only a single GFP-negative tumor in a total of 
186 tumors and none in the Mdr2KO model, we conclude that this 
tumor most likely arose from unlabeled hepatocytes. Moreover, 
we did not find any evidence that HSCs, a recently suggested 
alternative source for liver progenitors and hepatocytes (20), are 
a cellular source of HCC. Our findings are consistent with those 
of recent studies showing either a dominant or exclusive role of 
hepatocytes in hepatocyte repopulation, even in settings in which 
LPCs expanded and were considered a key source of newly gener-
ated hepatocytes (14–18). Likewise, our finding that murine HCCs 
abundance of progenitor/hepatoblast markers, but also carcino-
gen-free models in which HCC formation could be assessed with-
out the possibly confounding preferential metabolization of car-
cinogens by hepatocytes. Consistent with our data showing that 
99.4% and 100% of HCCs in the DEN+CCl4 and Mdr2KO models, 
respectively, were hepatocyte derived, we never observed HCCs 
originating from the LPC/biliary compartment. Because of the 
early age at which mice were injected, our hepatocyte labeling 
did not reach the levels that were seen in adult mice in previous 
studies (14, 40). As we did not label all hepatocytes but none-
Figure 6. A6-, K19-, and AFP-positive liver progenitors within HCCs are derived from hepatocytes. (A–D) To determine the cellular origin of liver progen-
itor cells within HCCs, colocalization of the progenitor markers A6 (A), K19 (B), and AFP (C) with mGFP was determined by confocal microcopy in tumor 
and nontumor areas of mTom-mGFP mice whose hepatocytes had been labeled via AAV8-Tbg-Cre and that were subsequently treated with DEN and 
CCl4. Quantification of mGFP of A6-, K19-, and AFP-positive cells in tumor and nontumor areas (n = 10 each) (D). (E–H) Colocalization of the progenitor/
hepatoblast markers A6 (E, serial sections), K19 (F, fluorescence), and AFP (G, serial sections) with YFP in tumor and nontumor areas of Opn-CreERT2 mice 
treated with 25 injections of DEN or with DEN+CCl4. Quantification of YFP with A6-, K19-, or AFP-positive cells (H) in tumor or nontumor areas. **P < 0.01, 
***P < 0.001 by 2-sided Student’s t test. ND, nondetectable. Scale bars: 50 μm (A–C and insert in E); 100 μm (E–G).
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source of HCC in patients. Future studies need to address the cel-
lular origin of human HCC, e.g., through the use of humanized 
mice for fate tracing and/or by showing that human hepatocytes 
have the same plasticity as mouse hepatocytes and are able to 
dedifferentiate into LPCs.
Methods
Tracing of liver progenitor cells in hepatocarcinogenesis. To track LPCs 
and biliary cells, we used the previously described Opn-CreERT2 mice 
(15). The Tg mice were on a CD1-enriched background, and males were 
used in all experiments. To achieve Cre-LoxP recombination, tamox-
ifen (T5648; Sigma-Aldrich) dissolved in corn oil at a concentration of 
30 mg/ml was injected i.p. at 100 mg/kg BW on day 21 pp unless other-
wise specified. In all experiments, Tg mice without tamoxifen injection 
(n ≥ 5) were used in parallel as a negative control for Cre recombina-
tion. Mice had free access to water and food at all times. To determine 
the contribution of LPCs to HCC, tamoxifen administered i.p. on day 
21 pp was followed by i.p. injections of DEN (35 mg/kg BW) for 25 
weeks starting at 6 weeks of age (n = 44) (36). At the start of chronic 
DEN treatment and up to the end of the experiment, 1 group of mice 
was fed a standard rodent chow diet (n = 22), while another group 
(n = 22) was placed on a high-fat diet (HFD) consisting of 60% satu-
rated fat (D12492; Research Diets). Because the effect of an HFD was 
to hasten tumor development, with no alteration in the nature of the 
tumors, data are presented for the entire group. In a second model, a 
single i.p. injection of DEN (6 mg/kg BW) (N0258; Sigma-Aldrich) was 
given on day 15 pp, and tamoxifen was administered i.p. either on days 
9–10 pp (n = 16) or on days 21–22 pp (n = 25), and mice were sacrificed at 
18 and 9 months of age, respectively. In a third experiment, mice were 
injected with tamoxifen on days 9–10 pp, followed by a single i.p. injec-
tion of DEN (6 mg/kg BW) on day 15 pp and 20 weekly injections of 
CCl4 (0.5 μl/g BW). Mice were sacrificed 2–4 weeks after the last CCl4 
dose (n = 6). Other tamoxifen-injected (day 21 pp) Opn-CreERT2 mice 
(n = 12) were treated with a CDE diet for 50 weeks starting at 8 weeks 
of age. Mice were sacrificed at 58 weeks of age or earlier, when the gen-
eral status of the mice was altered (BW loss, decreased activity, or pros-
tration). The DEN+CCl4 model was additionally used in K19-CreERT 
mice (39) (n = 5) coexpressing the mTom-mGFP Cre reporter; these 
mice received tamoxifen (80 μg/g i.p.) on day 10 pp and DEN on day 15 
pp, followed by 25 weekly injections of CCl4.
Tracing of hepatocytes in hepatocarcinogenesis. To genetically 
label hepatocytes, lox-stop-lox mTom-mGFP Cre reporter mice (52) 
were infected with AAV8-Tbg-Cre, resulting in mGFP expression in 
AAV8-Tbg-Cre–infected hepatocytes and in those of their offspring. 
For this purpose, mice were injected i.v. with 1 × 1011 genome copies 
of AAV8-Tbg-Cre (53) on day 12 pp. To induce HCC, AAV8-Tbg-Cre–
infected mice received a single i.p. dose of DEN (25 mg/kg BW) 
(Sigma- Aldrich) on day 15 pp. Subsequently, hepatic carcinogenesis 
was promoted by chronic injury using 3 different models. Four weeks 
after receiving DEN, some mice were treated with a total of 15 weekly 
injections of CCl4 (0.5 μl/g i.p., dissolved in oil at a ratio of 1:3, given 
once per week, n = 10) as described previously (38). For hepatocyte 
tracing in mice receiving DEN+CCl4, only mice with at least 90% 
hepatocyte labeling in nontumor sections were analyzed. Some mice 
were fed a DDC diet (n = 3) for 6 weeks starting 4 weeks after receiving 
DEN. Some mice were fed a CDE diet for 6 weeks starting 4 weeks 
after the DEN injection (n = 4).
are not derived from HSCs is consistent with our previous find-
ing that HSCs do not contribute to the hepatocyte or progenitor 
pool in multiple chronic injury mouse models (46). In agreement 
with the data presented here, a recent study using Hnf1b-CreERT 
labeling of the LPC/biliary compartment found no contribution 
of this compartment to HCC in DEN- or Mdr2KO-induced HCC 
(49), which complements the findings presented here. However, 
in contrast to our study, the authors did not positively identify the 
cellular source of HCC.
Our data demonstrate a fundamental difference between the 
liver and organs such as the intestine, skin, and hematopoetic sys-
tem, in which cancer is thought to be derived from stem cells (21–
25). This is consistent with the key role of the terminally differ-
entiated hepatocyte in generating new hepatocytes in the normal 
and injured liver (8, 14, 16–18). In view of the recently suggested 
hypothesis that the number of stem cell doublings determines 
cancer risk across various organs (50), the hepatocyte should be 
seen as a fully differentiated cell with stem cell–like functions that 
is at risk for malignant transformation with increasing numbers of 
doublings, similar to other stem cell populations. This hypothesis 
is compatible with the high rate of cancer observed in patients with 
chronic liver disease and constant hepatocyte turnover (51).
Recent studies found that hepatocytes have a high degree of 
plasticity and dedifferentiate into immature progenitors or biliary-
type cells in response to specific signals (40, 41). These data are 
consistent with our finding that hepatocyte-derived tumor cells 
express progenitor/biliary markers, suggesting a similar ability of 
hepatocyte-derived tumor cells to dedifferentiate into progenitor-
like cells. It is likely that such a dedifferentiation allows cells to 
adapt to specific challenges in the environment and presents an 
advantage for the tumor. Accordingly, tumors with a progenitor 
signature have worse prognosis (31).
Our study contains several limitations. Although we have 
confirmed hepatocyte origin and excluded LPC/biliary and HSC 
origins for a number of HCC models including various geno-
toxic and genetic models, we cannot fully exclude the possibility 
that progenitors have the ability to generate tumors in other set-
tings. As a wide range of infectious, metabolic, genetic, and toxic 
liver diseases can result in HCC development in patients, stud-
ies in additional hepatocarcinogenesis models — possibly using 
humanized mice to mimic HCC arising in the setting of hepatitis 
B virus–induced (HBV-induced) and HCV-induced hepatitis — 
are required to broaden the findings presented here. Also, recent 
fate-tracing studies in zebrafish have suggested that when hepa-
tocyte proliferation is completely blocked — which so far has not 
been achieved in murine injury models — regeneration occurs to a 
significant degree from the biliary compartment (19). However, a 
catastrophic event with complete hepatocyte failure is character-
istic of acute liver failure but not of HCC, in which injury is typi-
cally mild and chronic, similar to that in the animal models used. 
Our study mimicked several key features that are characteristic of 
human hepatocarcinogenesis such as chronic liver injury, fibro-
sis, and alterations in PTEN expression, but could not address 
possible intrinsic differences between mouse and human hepa-
tocytes or progenitor cells. As such, the contribution of the DR 
to functional hepatocytes in humans remains a matter of debate 
(48), and therefore it cannot be excluded that the DR is a cellular 
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fluorescence microscope (Carl Zeiss). For some images and for quanti-
fication, 4–6 sections were merged. Nonfluorescent images were taken 
with a Zeiss microscope coupled with an AxioCam camera (MR3; Carl 
Zeiss). Omission of the first Ab with an otherwise identical procedure or 
a sample lacking specific protein expression served as a negative control.
Quantification of hepatocyte and tumor labeling. Labeling effi-
ciency in the biliary/progenitor compartment was determined as pre-
viously reported (15). Briefly, K19-YFP double-positive cells relative to 
the total number of K19-positive cells in 25 random nontumor fields 
of view per section per mouse were quantified and expressed as a per-
centage. Timing for tamoxifen injection (days 9–21) or DEN treatment 
on day 15 did not modify the labeling efficiency. The percentage of 
A6-YFP and AFP-YFP double-positive cells was quantified using the 
same methodology.
For macroscopic imaging and determination of the percentage 
of GFP-labeled tumors, livers were visualized under a Leica MZ 16F 
fluorescence dissecting microscope. The ratio between green tumors 
and all tumors in each mouse was determined and expressed as a per-
centage. To quantify the GFP labeling for hepatocytes, frozen sections 
from nontumor tissue were used. Labeling efficiency was evaluated by 
quantification of GFP-positive hepatocytes relative to the total num-
ber of GFP-positive and mTomato-positive hepatocytes and expressed 
as a percentage.
The percentage of K19-GFP double-positive cells was deter-
mined by quantification of K19-GFP double-positive cells relative to 
the total K19-positive cell numbers in tumor and nontumor areas in 
DEN+CCl4-, DEN+CDE-, and DEN+DDC-treated mice groups. The 
percentage of A6-GFP double-positive cells was determined by the 
same approach.
RNA isolation and qPCR. RNA was isolated from cells and liver 
tissue by column purification and on-column DNAse treatment. 
After reverse transcription, mRNA levels were determined by qPCR 
on an Applied Biosystem 7300 Real-Time PCR cycler, using Applied 
Biosystems TaqMan primers and probes for Afp, Prom1, H19, mKi67, 
Golm1, Tspan8, Tff3, and Gpc3. All qPCRs were quantified using rela-
tive standard curves and normalized to 18S expression. mRNA levels 
in Opn-Cre samples were determined using SYBR green and results 
expressed as fold induction relative to control untreated liver using 
the ΔΔCt method.
Determination of hepatocytic and nonparenchymal cell markers 
in AAV8-Tbg-Cre–labeled liver cells. To determine which hepatic cell 
types were labeled by AAV8-Tbg-Cre, ZsGreen Cre reporter mice were 
infected with AAV8-Tbg-Cre. One week later, mice were sacrificed. 
Following perfusion with collagenase, green fluorescent cells were 
sorted by FACS from the entire liver cell suspension. After RNA isola-
tion and reverse transcription, qPCR was used to measure hepatocyte 
markers (Alb, Ttr), cholangiocyte markers (Krt7, Krt19), HSC markers 
(Des, Lrat), endothelial cell markers (Pecam, Vwf), and macrophage 
markers (Emr1, Cd68). To determine the percentage of these markers 
in the isolated green fluorescent cell fraction, cDNA from pure refer-
ence populations of primary cholangiocytes, HSCs, endothelial cells, 
and hepatic macrophages (46) was used.
Comparative genomic hybridization and syntenic analysis. Cus-
tom-designed 8x60K arrays (AMADID 41078; Agilent Technolo-
gies) were used for aCGH. Nineteen different formalin-fixed and 
paraffin-embedded HCC nodules and 2 unaffected liver tissues were 
microdissected, and genomic DNA was extracted using a DNAeasy 
Mdr2-KO–mediated hepatocarcinogenesis. To genetically label 
hepatocytes in the Mdr2KO model, lox-stop-lox ZsGreen Cre reporter 
mice (54) were infected with AAV8-Tbg-Cre, resulting in ZsGreen 
expression in AAV8-Tbg-Cre–infected hepatocytes and in those of 
their offspring. Mdr2KO mice (on an FVB background) that had been 
bred with ZsGreen Cre reporter mice (on a C57Bl/6 background) and 
backcrossed once with Mdr2KO mice (n = 9) were injected i.v. with 1 × 
1011 genome copies of AAV8-Tbg-Cre (53) on day 14 pp. Mdr2KO mice 
received additionally up to 25 weekly injections of CCl4 in order to 
accelerate hepatocarcinogenesis. Mice were sacrificed at 12 to 14 
months of age following screening for HCC by ultrasound.
PTEN-mediated hepatocarcinogenesis studies. As a nongenotoxic 
model of HCC, PtenWT/WT (n = 4) or Ptenfl/fl mice (n = 8), some of which 
were additionally carrying the mTom-mGFP Cre reporter, were 
injected with AAV8-Tbg-Cre (1 × 1011 genome copies i.v.) at 7 weeks of 
age, resulting in hepatocyte-specific deletion of Pten. To delete Pten 
specifically in the progenitor/ductular compartment, Krt19-CreERT 
mice (39) were crossed with PtenWT/WT (n = 4) or Ptenfl/fl mice (n = 4) and 
injected with tamoxifen (100 μg/ i.p.) at 2 weeks of age.
Lrat-Cre–mediated HSC labeling. To determine whether HSCs 
might be a cellular source for HCC, Lrat-Cre mice coexpressing 
ZsGreen or TdTomato Cre reporters (54) were injected i.p. with DEN 
(25 mg/kg BW) on day 15 pp, followed by 20 weekly injections of 
CCl4 (n = 4). Mice were sacrificed 2 weeks after the last CCl4 injec-
tion. Mdr2KO mice coexpressing Lrat-Cre and ZsGreen or TdTomato 
(n = 8) served as a second HCC model. Mice were sacrificed at 12 to 14 
months of age following HCC screening by ultrasound.
Immunohistochemical and immunofluorescence analysis. Following 
sacrifice and rapid excision of the liver, tumor and nontumor tissues 
were macroscopically identified and either fixed in 4% formalin for 
histological examination or snap-frozen in liquid nitrogen for gene 
expression analysis.
For histological analysis, 4-μm formalin-fixed, paraffin-embedded 
liver sections and frozen liver sections were analyzed. For immunohis-
tochemical analysis, slides were incubated for 1 hour at 37°C with pri-
mary Abs against YFP (catalog Ab6673; Abcam); cytokeratin 19 (Devel-
opmental Studies Hybridoma Bank, University of Iowa); HNF4α (catalog 
PP-H1415 from R&D Systems or catalog sc-6556 from Santa Cruz Bio-
technology Inc.); AFP (catalog 14550-1-AP; Proteintech); OPN (catalog 
AF808; R&D Systems); α–smooth muscle actin (α-SMA) (MyBioSource); 
Ki67 (Tec3; Dako); desmin (catalog RB-9014-P; Lab Vision); pancytok-
eratin (catalog Z0622; Dako); CD31 (catalog 14-0311-81; eBioscience); 
progenitor marker A6 (55) (a gift of Valentina Factor, NIH, Bethesda, 
Maryland, USA) or F4/80 (catalog MCA497A64; AbD Serotec); col-
lagen IV (catalog CL50451 AP-1; Cedarlane); Ki67 (rabbit monoclonal; 
Thermo Scientific); Gp73 (catalog sc-48001; Santa Cruz Biotechnology 
Inc.); or glutamine synthetase (catalog ab16802; Abcam). Detection 
was performed using either fluorescent secondary Abs with various flu-
orescent conjugates: anti-rabbit (donkey anti-rabbit, A21207; chicken 
anti-rat A21472; or chicken anti-goat A21468; all used at 1:200; all from 
Invitrogen), or with HRP-conjugated secondary Abs (anti-rat Ig-HRP, 
E0468; anti-goat Ig-HRP P0449; anti-mouse Envision K4001; or 
anti-rabbit Envision K4003; used at 1:50 to 1:200; all from Dako), with 
subsequent DAB exposure and hematoxylin counterstaining. For DAB 
staining, serial sections were used. Fluorescent images were taken on 
a Nikon A1 confocal laser microscope (Nikon Instruments) using a ×20 
standard lens or ×40 and ×60 oil-immersion lenses or an Axiovert 200 
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